NEW YORK -Nuvelo Inc. shares surged Wednesday after the drug developer said it re-initiated a late stage clinical trial of alfimeprase, its lead blood thinner candidate.The Phase 3 trial is designed to determine if a single dose of alfimeprase can restore function to blocked central venous catheters within 15 minutes. The company expects trial data next year.
